Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces...